Publication Name	World Journal of Clinical Oncology
Manuscript ID	7082
Country	Italy

Received	2013-11-03 20:24
Peer-Review Started	2013-11-04 15:10
First Decision by Editorial Office Director
Return for Revision	2013-11-19 16:02
Revised	2013-12-03 19:04
Publication Fee Transferred
Second Decision by Editor	2014-01-20 08:50
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2014-01-20 09:56
Articles in Press
Edit the Manuscript by Language Editor	2014-02-26 03:09
Typeset the Manuscript	2014-05-07 14:47
Publish the Manuscript Online	2014-05-12 18:06

ISSN	2218-4333 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Letter to the Editor
Article Title	Meta-regression of treatments for metastatic colorectal cancer: Quantifying incremental benefit from 2000 to 2012
Manuscript Source	Invited Manuscript
All Author List	Andrea Messori, Margherita Conti, Valeria Fadda, Dario Maratea and Sabrina Trippoli
Funding Agency and Grant Number
Corresponding Author	Dr. Andrea Messori, HTA Unit, ESTAV Toscana Centro, Regional Health Service, Via San Salvi 12, 50100 Firenze, Italy. andrea.messori.it@gmail.com
Key Words	Metastatic colorectal cancer; Chemotherapy; 5-Fluorouracil; Chemotherapy; Irinotecan; Oxaliplatin; Bevacizumab; Meta-analysis; Meta-regression
Core Tip	We conducted out a meta-regression in which randomized studies from 2000 to 2012 were evaluated and the temporal trend was analyzed [end points: overall survival (OS), and progression-free survival (PFS)]. Our literature search identified all trials employing a fluoropyrimidine regimen. Covariates included temporal trend, arm allocation and Kirsten rat sarcoma status. According to meta-regression of 130 treatment arms, the improvement between 2002 and 2012 was from 14.9 to 18.8 mo for OS (P < 0.001) and from 5.7 to 8.1 mo for PFS (P < 0.001). Our study indicates that OS and PFS have improved from 2000 to 2012 but the extent of this improvement is small.
Publish Date	2014-05-12 18:06
Citation	Messori A, Conti M, Fadda V, Maratea D, Trippoli S. Metaregression of treatments for metastatic colorectal cancer: Quantifying incremental benefit from 2000 to 2012. World J Clin Oncol 2014; 5(2): 191-193
URL	http://www.wjgnet.com/2218-4333/full/v5/i2/191.htm
DOI	http://dx.doi.org/10.5306/wjco.v5.i2.191

Full Article (PDF)	WJCO-5-191.pdf
Full Article (Word)	WJCO-5-191.doc
Manuscript File	7082-Review.doc
Answering Reviewers	7082-Answering reviews.pdf
Copyright License Agreement	7082-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	7082-Language certificate.pdf
Peer-review Report	7082-Peer review.pdf
Scientific Editor Work List	7082-Scientific editor work list.doc